

Custom Antibody Market by Service (Development, Purification, Fragmentation, Labeling), Type (mAbs, pAbs, rAbs), Source (Rabbit, Mice), Application (Research, Therapeutics), Indication (Oncology, Immunology, Infectious, CVD) - Global Forecast to 2029

Market Report | 2024-06-05 | 377 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The custom antibody market is expected to reach USD 901 million in 2029 from USD 579 million in 2024, at a CAGR of 9.2% during the forecast period.

The growth of this market can be attributed to the increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases, which has heightened the demand for targeted and effective therapeutic antibodies. Advancements in biotechnology and genetic engineering have significantly improved the development and production of custom antibodies, enhancing their specificity and efficacy.

"The antibody development segment accounted for the largest share by service in the custom antibody market 2023."

The custom antibody market by service is segmented into antibody development, antibody production & purification, and antibody fragmentation & labeling. The antibody development is further subsegmented into antigen preparation, immunization & hybridoma production, and antibody characterization. In 2023, the antibody development segment accounted for the largest share of the service segment in the global custom antibody market. Factors such as the increasing use of antibodies in drug delivery systems, such as antibody-drug conjugates (ADCs), has expanded the need for custom antibody development.

"The Asia Pacific region is growing at the highest CAGR in the custom antibody market from 2024 to 2029."

The Asia Pacific region is expected to grow at the highest growth rate during the forecast period. Various factors including emerging economies, increased prevalence of chronic diseases, and large patient pool undergoing advanced medical treatment are factors driving the high growth of the APAC market.

Increased research investments from government funding are expected to boost the growth of the custom antibody market in the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Asia Pacific region. As the region continues to invest in drug development, there is a growing demand for research antibodies driving demand for custom antibodies.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side- 70% and Demand Side 30%

-□By Designation: C-level Executives - 55%, Director-level - 20%, and Others - 25%

-□By Region: North America -45%, Europe -20%, Asia-Pacific -20%, Latin America -10%, Middle East -3%, and Africa-2%.

List of Companies Profiled in the Report:

-□Thermo Fisher Scientific Inc. (US)

-□GenScript (US)

-□Merck KGaA (Germany)

-□Bio-Rad Laboratories, Inc. (US)

-□Agilent Technologies, Inc. (US)

-□Revvity, Inc. (US)

-□Bio-Techne (US)

-□ROCKLAND IMMUNOCHEMICALS, INC. (US)

-□Laboratory Corporation of America Holdings (US)

-□Inotiv (US)

-□Danaher Corporation (US)

-□Sino Biological, Inc. (China)

-□KANEKA CORPORATION (Japan)

-□OriGene Technologies, Inc. (US)

-□Absolute Biotech (US)

-□Biointron Biologics (China)

-□Cell Signaling Technology, Inc. (US)

-□Curia Global, Inc. (US)

-□Mabtech (Sweden)

-□ACROBiosystems (US)

-□Elabsience Bionovation Inc. (US)

-□Creative Diagnostics (US)

-□CUSABIO TECHNOLOGY LLC (US)

-□BioGenes GmbH (Germany)

-□RayBiotech, Inc. (US)

-□Proteintech Group, Inc (US)

-□IMGENEX INDIA Pvt Ltd. (India)

-□Synbio Technologies (US)

-□ProSci Incorporated (US)

-□Creative Biolabs (US)

Research Coverage:

This research report categorizes the custom antibody market by service (antibody development (antigen preparation, immunization & hybridoma production, and antibody characterization), antibody production & purification, and antibody fragmentation & labeling, type (monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and others), source (mice, rabbits, and others), application (research, and therapeutics), indication (oncology, infectious diseases, immunology, neurobiology, cardiovascular diseases, and other indications), end user (pharmaceutical & biotechnologies companies, academic & research institutes, and contract research organizations), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

provides in-depth information on significant factors influencing the growth of the custom antibody market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches, and acquisitions within the custom antibody market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall custom antibody market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (growing importance of custom antibodies in precision medicine, use of antibodies in biomarker identification and validation, rising research activities and funding investments for antibody development, advancement in biotechnology and genetic engineering), restraints (High cost and time-consuming antibody development from transgenic animals), opportunities (rising therapeutic and diagnostic application of antibodies, high scope for growth in emerging economies), and challenges (challenges associated with safety and stability) influencing the growth of the market.

-□Product Development/Innovation: Detailed insights on newly launched services of the custom antibody market

-□Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

-□Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the custom antibody market

-□Competitive Assessment: Thermo Fisher Scientific Inc. (US), GenScript (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Revvity, Inc. (US), Bio-Techne (US), ROCKLAND IMMUNOCHEMICALS, INC. (US), Laboratory Corporation of America Holdings (US), Inotiv (US), Danaher Corporation (US), Sino Biological, Inc. (China), KANEKA CORPORATION (Japan), OriGene Technologies, Inc. (US), Absolute Biotech (US), Biointron Biologics (China), Cell Signaling Technology, Inc. (US), Curia Global, Inc. (US), Mabtech (Sweden), ACROBiosystems (US), Elabscience Bionovation Inc. (US), Creative Diagnostics (US), CUSABIO TECHNOLOGY LLC (US), BioGenes GmbH (Germany), RayBiotech, Inc. (US), Proteintech Group, Inc (US), IMGENEX INDIA Pvt Ltd. (India), Synbio Technologies (US), ProSci Incorporated (US), Creative Biolabs (US) among others in the market.

Table of Contents:

1	INTRODUCTION	51
1.1	STUDY OBJECTIVES	51
1.2	MARKET DEFINITION	52
1.2.1	INCLUSIONS AND EXCLUSIONS OF STUDY	52
1.3	MARKET SCOPE	53
1.3.1	MARKETS COVERED	53
1.3.2	REGIONS COVERED	54
1.4	YEARS CONSIDERED	54
1.5	CURRENCY CONSIDERED	55
1.6	STAKEHOLDERS	55
1.7	SUMMARY OF CHANGES	55
1.8	RECESSION IMPACT	56
2	RESEARCH METHODOLOGY	57
2.1	RESEARCH DATA	57
FIGURE 1	RESEARCH DESIGN	57
2.1.1	SECONDARY DATA	58
2.1.2	PRIMARY DATA	59
FIGURE 2	CUSTOM ANTIBODY MARKET: BREAKDOWN OF PRIMARIES	59

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.2	MARKET ESTIMATION METHODOLOGY	60
	FIGURE 3	CUSTOM ANTIBODY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
2.2.1	MARKET ESTIMATION	60
	FIGURE 4	MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
	FIGURE 5	ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2023)
2.2.1.1	Insights of primary experts	63
	FIGURE 6	MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.2.2	SEGMENTAL MARKET SIZE ESTIMATION	63
	FIGURE 7	MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3	MARKET GROWTH RATE PROJECTIONS	65
	FIGURE 8	CUSTOM ANTIBODY MARKET: CAGR PROJECTIONS
	TABLE 1	IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
2.4	MARKET BREAKDOWN AND DATA TRIANGULATION	67
	FIGURE 9	DATA TRIANGULATION METHODOLOGY
2.5	RESEARCH ASSUMPTIONS	68
2.6	LIMITATIONS	68
2.7	RISK ANALYSIS	69
2.8	RECESSION IMPACT ANALYSIS	69
3	EXECUTIVE SUMMARY	71
	FIGURE 10	CUSTOM ANTIBODY MARKET, BY SERVICE, 2024 VS. 2029 (USD MILLION)
	FIGURE 11	CUSTOM ANTIBODY MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
	FIGURE 12	CUSTOM ANTIBODY MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION)
	FIGURE 13	CUSTOM ANTIBODY MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION)
	FIGURE 14	CUSTOM ANTIBODY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
	FIGURE 15	GEOGRAPHICAL SNAPSHOT OF CUSTOM ANTIBODY MARKET
4	PREMIUM INSIGHTS	76
4.1	CUSTOM ANTIBODY MARKET OVERVIEW	76
	FIGURE 16	GROWING IMPORTANCE OF CUSTOM ANTIBODIES IN PRECISION MEDICINE TO DRIVE GROWTH
4.2	ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SERVICE AND COUNTRY (2023)	77
	FIGURE 17	ANTIBODY DEVELOPMENT SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC CUSTOM ANTIBODY MARKET IN 2023
4.3	CUSTOM ANTIBODY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	78
	FIGURE 18	CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
4.4	CUSTOM ANTIBODY MARKET SHARE, BY END USER, 2023	78
	FIGURE 19	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
5	MARKET OVERVIEW	79
5.1	INTRODUCTION	79
5.2	MARKET DYNAMICS	79
	FIGURE 20	CUSTOM ANTIBODY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
	TABLE 2	CUSTOM ANTIBODY MARKET: IMPACT ANALYSIS
5.2.1	DRIVERS	80
5.2.1.1	Growing importance of custom antibodies in precision medicine	80
5.2.1.2	Use of antibodies in biomarker identification and validation	81
5.2.1.3	Rising research activities and funding investments for antibody development	81
5.2.1.4	Advancements in biotechnology and genetic engineering	82
5.2.2	RESTRAINTS	83
5.2.2.1	High cost and time-consuming antibody development from transgenic animals	83

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.2.3	OPPORTUNITIES	83
5.2.3.1	Rising therapeutic and diagnostic application of antibodies	83
5.2.3.2	High scope for growth in emerging economies	84
5.2.4	CHALLENGES	84
5.2.4.1	Challenges associated with safety and stability	84
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	85
FIGURE 21	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	85
5.4	REGULATORY LANDSCAPE	86
5.4.1	REGULATORY SCENARIO	86
5.4.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	86
TABLE 3	NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	86
TABLE 4	EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	87
TABLE 5	ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	89
TABLE 6	REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	91
5.5	VALUE CHAIN ANALYSIS	92
FIGURE 22	CUSTOM ANTIBODY MARKET: VALUE CHAIN ANALYSIS	92
5.6	TECHNOLOGICAL ANALYSIS	93
5.6.1	KEY TECHNOLOGIES	93
5.6.1.1	Hybridoma technology	93
5.6.1.2	Phage display technology	94
5.6.1.3	Recombinant DNA technology	94
5.6.2	COMPLIMENTARY TECHNOLOGIES	94
5.6.2.1	Next-generation sequencing	94
5.6.2.2	High-throughput screening	94
5.6.3	ADJACENT TECHNOLOGIES	95
5.6.3.1	Single-cell analysis technology	95
5.6.3.2	Peptide synthesis	95
5.6.3.3	Protein engineering	95
5.7	PRICING ANALYSIS	95
5.7.1	INDICATIVE PRICING ANALYSIS, BY SERVICE, 2023 & 2024	96
TABLE 7	INDICATIVE PRICE ANALYSIS, BY SERVICE, 2023 & 2024	96
5.7.2	INDICATIVE PRICING ANALYSIS, BY REGION, 2023 & 2024	96
TABLE 8	INDICATIVE PRICE ANALYSIS, BY REGION, 2023 & 2024	96
5.8	PATENT ANALYSIS	96
5.8.1	METHODOLOGY	96
5.8.2	PATENTS FILED, BY DOCUMENT TYPE, 2014-2024	96
TABLE 9	PATENTS FILED, 2014-2024	96
5.8.3	INNOVATION AND PATENT APPLICATIONS	97
FIGURE 23	TOTAL NUMBER OF PATENTS GRANTED, 2014-2024	97
5.8.4	TOP APPLICANTS	97
FIGURE 24	TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014-2024	97
TABLE 10	TOP 20 PATENT OWNERS IN CUSTOM ANTIBODY MARKET, 2014-2024	98
TABLE 11	INDICATIVE LIST OF PATENTS IN CUSTOM ANTIBODY MARKET, 2022-2024	99
?		
5.9	SUPPLY CHAIN ANALYSIS	100
FIGURE 25	CUSTOM ANTIBODY MARKET: SUPPLY CHAIN ANALYSIS	101
5.10	ECOSYSTEM ANALYSIS	101

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 26 □ CUSTOM ANTIBODY MARKET: ECOSYSTEM ANALYSIS □ 101

5.10.1 □ CUSTOM ANTIBODY RAW MATERIAL SUPPLIERS □ 102

TABLE 12 □ CUSTOM ANTIBODY MARKET: RAW MATERIAL SUPPLIERS □ 102

5.10.2 □ CUSTOM ANTIBODY SERVICE PROVIDERS □ 102

TABLE 13 □ CUSTOM ANTIBODY MARKET: SERVICE PROVIDERS □ 102

5.10.3 □ CUSTOM ANTIBODY END USERS □ 102

TABLE 14 □ CUSTOM ANTIBODY MARKET: END USERS □ 103

5.10.4 □ CUSTOM ANTIBODY REGULATORY AUTHORITIES □ 103

TABLE 15 □ CUSTOM ANTIBODY MARKET: REGULATORY AUTHORITIES □ 103

5.11 □ KEY CONFERENCES AND EVENTS, 2024-2025 □ 104

TABLE 16 □ CUSTOM ANTIBODY MARKET: LIST OF CONFERENCES AND EVENTS, 2024-2025 □ 104

5.12 □ PORTER'S FIVE FORCES ANALYSIS □ 105

FIGURE 27 □ CUSTOM ANTIBODY MARKET: PORTER'S FIVE FORCES ANALYSIS □ 105

5.12.1 □ IMPACT OF PORTER'S FIVE FORCES ON CUSTOM ANTIBODY MARKET □ 105

TABLE 17 □ CUSTOM ANTIBODY MARKET: PORTER'S FIVE FORCES ANALYSIS □ 105

5.12.2 □ INTENSITY OF COMPETITIVE RIVALRY □ 106

5.12.3 □ BARGAINING POWER OF SUPPLIERS □ 106

5.12.4 □ BARGAINING POWER OF BUYERS □ 106

5.12.5 □ THREAT OF SUBSTITUTES □ 106

5.12.6 □ THREAT OF NEW ENTRANTS □ 106

5.13 □ KEY STAKEHOLDERS AND BUYING CRITERIA □ 107

5.13.1 □ KEY STAKEHOLDERS IN BUYING PROCESS □ 107

FIGURE 28 □ INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CUSTOM ANTIBODIES □ 107

5.13.2 □ CUSTOM ANTIBODY MARKET: BUYING CRITERIA FOR END USERS □ 108

FIGURE 29 □ KEY BUYING CRITERIA FOR END USERS OF CUSTOM ANTIBODIES □ 108

TABLE 18 □ BUYING CRITERIA FOR CUSTOM ANTIBODIES, BY END USER □ 108

5.14 □ INVESTMENT AND FUNDING SCENARIO □ 109

TABLE 19 □ RESEARCH FUNDING BY VARIOUS INSTITUTES/CENTERS, 2020-2024 (USD MILLION) □ 109

6 □ CUSTOM ANTIBODY MARKET, BY SERVICE □ 110

6.1 □ INTRODUCTION □ 111

TABLE 20 □ CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) □ 111

6.2 □ ANTIBODY DEVELOPMENT □ 111

TABLE 21 □ CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) □ 112

TABLE 22 □ CUSTOM ANTIBODY DEVELOPMENT MARKET, BY REGION, 2022-2029 (USD MILLION) □ 112

TABLE 23 □ NORTH AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION) □ 113

TABLE 24 □ EUROPE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION) □ 113

TABLE 25 □ ASIA PACIFIC: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION) □ 114

TABLE 26 □ LATIN AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION) □ 114

TABLE 27 □ MIDDLE EAST: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION) □ 115

TABLE 28 □ GCC COUNTRIES: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION) □ 115

6.2.1 □ ANTIBODY CHARACTERIZATION □ 115

6.2.1.1 □ Growing adoption of therapeutic antibodies to drive growth □ 115

TABLE 29 □ ANTIBODY CHARACTERIZATION MARKET, BY REGION, 2022-2029 (USD MILLION) □ 116

TABLE 30 □ NORTH AMERICA: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) □ 116

TABLE 31 □ EUROPE: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) □ 117

TABLE 32 □ ASIA PACIFIC: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) □ 117

TABLE 33 □ LATIN AMERICA: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) □ 118

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 34 MIDDLE EAST: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 118

TABLE 35 GCC COUNTRIES: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 118

6.2.2 ANTIGEN PREPARATION 119

6.2.2.1 Rising use of research antibodies to support market growth 119

TABLE 36 ANTIGEN PREPARATION MARKET, BY REGION, 2022-2029 (USD MILLION) 120

TABLE 37 NORTH AMERICA: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 120

TABLE 38 EUROPE: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 121

TABLE 39 ASIA PACIFIC: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 121

TABLE 40 LATIN AMERICA: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 122

TABLE 41 MIDDLE EAST: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 122

TABLE 42 GCC COUNTRIES: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 122

6.2.3 IMMUNIZATION & HYBRIDOMA PRODUCTION 123

6.2.3.1 Rising demand for therapeutic antibodies to drive market 123

TABLE 43 IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY REGION, 2022-2029 (USD MILLION) 123

TABLE 44 NORTH AMERICA: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 124

TABLE 45 EUROPE: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 124

TABLE 46 ASIA PACIFIC: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 125

TABLE 47 LATIN AMERICA: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 125

TABLE 48 MIDDLE EAST: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 126

TABLE 49 GCC COUNTRIES: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 126

6.3 ANTIBODY PRODUCTION & PURIFICATION 126

6.3.1 RESEARCH & DEVELOPMENT IN LIFE SCIENCES TO BOOST MARKET GROWTH 126

TABLE 50 CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY REGION, 2022-2029 (USD MILLION) 127

TABLE 51 NORTH AMERICA: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 127

TABLE 52 EUROPE: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 128

TABLE 53 ASIA PACIFIC: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 128

TABLE 54 LATIN AMERICA: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 129

TABLE 55 MIDDLE EAST: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 129

TABLE 56 GCC COUNTRIES: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 129

6.4 ANTIBODY FRAGMENTATION & LABELING 130

6.4.1 RISING RESEARCH AND CLINICAL APPLICATIONS TO DRIVE GROWTH 130

TABLE 57 CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY REGION, 2022-2029 (USD MILLION) 131

TABLE 58 NORTH AMERICA: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 131

TABLE 59 EUROPE: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 132

TABLE 60 ASIA PACIFIC: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 132

TABLE 61 LATIN AMERICA: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 133

TABLE 62 MIDDLE EAST: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 133

TABLE 63 GCC COUNTRIES: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 133

7 CUSTOM ANTIBODY MARKET, BY TYPE 134

7.1 INTRODUCTION 135

TABLE 64 CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 135

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.2 MONOCLONAL ANTIBODIES 135

7.2.1 HIGH DEGREE OF SENSITIVITY AND PRECISION TO BOOST MARKET GROWTH 135

TABLE 65 CUSTOM MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION) 136

TABLE 66 NORTH AMERICA: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 136

TABLE 67 EUROPE: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 137

TABLE 68 ASIA PACIFIC: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 137

TABLE 69 LATIN AMERICA: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 138

TABLE 70 MIDDLE EAST: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 138

TABLE 71 GCC COUNTRIES: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 138

7.3 POLYCLONAL ANTIBODIES 139

7.3.1 VERSATILITY AND EFFICACY IN RECOGNITION OF ANTIGEN SITES TO BOOST MARKET GROWTH 139

TABLE 72 CUSTOM POLYCLONAL ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION) 140

TABLE 73 NORTH AMERICA: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 140

TABLE 74 EUROPE: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 141

TABLE 75 ASIA PACIFIC: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 141

TABLE 76 LATIN AMERICA: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 142

TABLE 77 MIDDLE EAST: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 142

TABLE 78 GCC COUNTRIES: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 142

7.4 RECOMBINANT ANTIBODIES 143

7.4.1 RISING RESEARCH & DEVELOPMENT IN LIFE SCIENCES INDUSTRY TO BOOST MARKET GROWTH 143

TABLE 79 CUSTOM RECOMBINANT ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION) 144

TABLE 80 NORTH AMERICA: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 144

TABLE 81 EUROPE: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 145

TABLE 82 ASIA PACIFIC: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 145

TABLE 83 LATIN AMERICA: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 146

TABLE 84 MIDDLE EAST: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 146

TABLE 85 GCC COUNTRIES: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 146

7.5 OTHER CUSTOM ANTIBODIES 147

TABLE 86 OTHER CUSTOM ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION) 147

TABLE 87 NORTH AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 148

TABLE 88 EUROPE: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 148

TABLE 89 ASIA PACIFIC: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 149

TABLE 90 LATIN AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 149

TABLE 91 MIDDLE EAST: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 150

TABLE 92 GCC COUNTRIES: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 150

8 CUSTOM ANTIBODY MARKET, BY SOURCE 151

8.1 INTRODUCTION 152

TABLE 93 CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 152

8.2 MICE 152

8.2.1 WIDESPREAD AVAILABILITY AND COST-EFFECTIVENESS TO PROPEL MARKET 152

TABLE 94 CUSTOM ANTIBODY MARKET FOR MICE, BY REGION, 2022-2029 (USD MILLION) 153

TABLE 95 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION) 153

TABLE 96 EUROPE: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION) 154

TABLE 97 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION) 154

TABLE 98 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION) 155

TABLE 99 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION) 155

TABLE 100 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION) 155

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.3 RABBITS 156

8.3.1 ABILITY TO GENERATE HIGH ANTIBODY DIVERSITY WITH OPTIMAL AFFINITY TO DRIVE MARKET 156

TABLE 101 CUSTOM ANTIBODY MARKET FOR RABBITS, BY REGION, 2022-2029 (USD MILLION) 156

TABLE 102 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION) 157

TABLE 103 EUROPE: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION) 157

TABLE 104 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION) 158

TABLE 105 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION) 158

TABLE 106 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION) 159

TABLE 107 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION) 159

8.4 OTHER SOURCES 159

TABLE 108 CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY REGION, 2022-2029 (USD MILLION) 160

TABLE 109 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION) 161

TABLE 110 EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION) 161

TABLE 111 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION) 162

TABLE 112 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION) 162

TABLE 113 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION) 162

TABLE 114 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION) 163

9 CUSTOM ANTIBODY MARKET, BY APPLICATION 164

9.1 INTRODUCTION 165

TABLE 115 CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 165

9.2 RESEARCH 165

9.2.1 HIGH DEGREE OF SENSITIVITY AND SPECIFICITY TO BOOST MARKET GROWTH 165

TABLE 116 CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2022-2029 (USD MILLION) 166

TABLE 117 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 166

TABLE 118 EUROPE: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 167

TABLE 119 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 167

TABLE 120 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 168

TABLE 121 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 168

TABLE 122 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 168

9.3 THERAPEUTIC 169

9.3.1 RISING DEMAND FOR ANTIBODY-BASED THERAPEUTICS TO SUPPORT MARKET GROWTH 169

TABLE 123 CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2022-2029 (USD MILLION) 169

TABLE 124 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 170

TABLE 125 EUROPE: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 170

TABLE 126 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 171

TABLE 127 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 171

TABLE 128 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 172

TABLE 129 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 172

10 CUSTOM ANTIBODY MARKET, BY INDICATION 173

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.1 INTRODUCTION 174

TABLE 130 CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 174

10.2 ONCOLOGY 174

10.2.1 RISING PREVALENCE OF CANCER TO DRIVE MARKET 174

TABLE 131 CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY REGION, 2022-2029 (USD MILLION) 175

TABLE 132 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 175

TABLE 133 EUROPE: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 176

TABLE 134 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 176

TABLE 135 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 177

TABLE 136 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 177

TABLE 137 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 177

10.3 INFECTIOUS DISEASES 178

10.3.1 USE OF ANTIBODIES IN VACCINE & THERAPEUTIC DEVELOPMENT TO BOOST MARKET GROWTH 178

TABLE 138 CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION) 178

TABLE 139 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 179

TABLE 140 EUROPE: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 179

TABLE 141 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 180

TABLE 142 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 180

TABLE 143 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 181

TABLE 144 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 181

?

10.4 IMMUNOLOGY 181

10.4.1 RISING NUMBER OF PRODUCTS UNDER CLINICAL STUDIES TO BOOST MARKET GROWTH 181

TABLE 145 CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY REGION, 2022-2029 (USD MILLION) 182

TABLE 146 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 183

TABLE 147 EUROPE: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 183

TABLE 148 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 184

TABLE 149 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 184

TABLE 150 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 185

TABLE 151 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 185

10.5 NEUROBIOLOGY 185

10.5.1 RISING DEMAND FOR ANTIBODIES IN NEURODEGENERATIVE DISEASES TO PROPEL MARKET 185

TABLE 152 CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY REGION, 2022-2029 (USD MILLION) 186

TABLE 153 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 186

TABLE 154 EUROPE: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 187

TABLE 155 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 187

TABLE 156 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 188

TABLE 157 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 188

TABLE 158 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 188

10.6 CARDIOVASCULAR DISEASES 189

10.6.1 RISING DEMAND FOR CVD BIOMARKERS TO DRIVE MARKET 189

TABLE 159 CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2029 (USD MILLION) 189

TABLE 160 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 190

TABLE 161 EUROPE: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 190

TABLE 162 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 191

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 163 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) □ 191

TABLE 164 □ MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) □ 192

TABLE 165 □ GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) □ 192

10.7 □ OTHER INDICATIONS □ 192

TABLE 166 □ CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY REGION, 2022-2029 (USD MILLION) □ 193

TABLE 167 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) □ 194

TABLE 168 □ EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) □ 194

TABLE 169 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) □ 195

TABLE 170 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) □ 195

TABLE 171 □ MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) □ 196

TABLE 172 □ GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) □ 196

11 □ CUSTOM ANTIBODY MARKET, BY END USER □ 197

11.1 □ INTRODUCTION □ 198

TABLE 173 □ CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) □ 198

11.2 □ PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES □ 198

11.2.1 □ RISING DEMAND FOR THERAPEUTIC ANTIBODIES TO BOOST MARKET GROWTH □ 198

TABLE 174 □ CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION) □ 199

TABLE 175 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) □ 199

TABLE 176 □ EUROPE: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) □ 200

TABLE 177 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) □ 200

TABLE 178 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) □ 201

TABLE 179 □ MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) □ 201

TABLE 180 □ GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) □ 201

11.3 □ ACADEMIC & RESEARCH INSTITUTES □ 202

11.3.1 □ GROWING INDUSTRY-ACADEMIA COLLABORATIONS TO DRIVE MARKET □ 202

TABLE 181 □ CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION) □ 202

TABLE 182 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) □ 203

TABLE 183 □ EUROPE: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) □ 203

TABLE 184 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) □ 204

TABLE 185 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) □ 204

TABLE 186 □ MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) □ 205

TABLE 187 □ GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

MILLION) 205

11.4 CONTRACT RESEARCH ORGANIZATIONS 205

11.4.1 INCREASING DEMAND FOR MABS AND ADC SERVICES TO PROPEL MARKET 205

TABLE 188 CUSTOM ANTIBODY MARKET FOR CROS, BY REGION, 2022-2029 (USD MILLION) 206

TABLE 189 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION) 206

TABLE 190 EUROPE: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION) 207

TABLE 191 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION) 207

TABLE 192 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION) 208

TABLE 193 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION) 208

TABLE 194 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION) 208

12 CUSTOM ANTIBODY MARKET, BY REGION 209

12.1 INTRODUCTION 210

TABLE 195 CUSTOM ANTIBODY MARKET, BY REGION, 2022-2029 (USD MILLION) 210

12.2 NORTH AMERICA 210

FIGURE 30 NORTH AMERICA: CUSTOM ANTIBODY MARKET SNAPSHOT 211

TABLE 196 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 212

TABLE 197 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 212

TABLE 198 NORTH AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 212

TABLE 199 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 213

TABLE 200 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 213

TABLE 201 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 213

TABLE 202 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 214

TABLE 203 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 214

12.2.1 US 214

12.2.1.1 Growing number of FDA approvals for monoclonal antibody therapies to drive market 214

FIGURE 31 NIH FUNDING IN LAST 10 YEARS FOR HEALTHCARE R&D (2014-2024) 215

TABLE 204 US: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 216

TABLE 205 US: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 216

TABLE 206 US: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 216

TABLE 207 US: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 217

TABLE 208 US: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 217

TABLE 209 US: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 217

TABLE 210 US: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 218

12.2.2 CANADA 218

12.2.2.1 Increasing incidence of cancer to support market growth 218

TABLE 211 CANADA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 219

TABLE 212 CANADA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 219

TABLE 213 CANADA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 220

TABLE 214 CANADA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 220

TABLE 215 CANADA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 220

TABLE 216 CANADA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 221

TABLE 217 CANADA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 221

12.2.3 NORTH AMERICA: RECESSION IMPACT 221

12.3 EUROPE 222

TABLE 218 EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 222

TABLE 219 EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 223

TABLE 220 EUROPE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 223

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 221 □ EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) □ 224

TABLE 222 □ EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) □ 224

TABLE 223 □ EUROPE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) □ 224

TABLE 224 □ EUROPE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) □ 225

TABLE 225 □ EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) □ 225

12.3.1 □ GERMANY □ 225

12.3.1.1 □ Growing investment in ADCs development to drive market □ 225

TABLE 226 □ GERMANY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) □ 226

TABLE 227 □ GERMANY: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) □ 226

TABLE 228 □ GERMANY: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) □ 227

TABLE 229 □ GERMANY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) □ 227

TABLE 230 □ GERMANY: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) □ 227

TABLE 231 □ GERMANY: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) □ 228

TABLE 232 □ GERMANY: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) □ 228

12.3.2 □ UK □ 228

12.3.2.1 □ Life sciences funding with biotech firms to boost adoption of custom antibodies □ 228

TABLE 233 □ UK: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) □ 229

TABLE 234 □ UK: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) □ 229

TABLE 235 □ UK: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) □ 230

TABLE 236 □ UK CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) □ 230

TABLE 237 □ UK: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) □ 230

TABLE 238 □ UK: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) □ 231

TABLE 239 □ UK: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) □ 231

12.3.3 □ FRANCE □ 231

12.3.3.1 □ Increasing government investments in pharmaceutical industry to drive growth □ 231

TABLE 240 □ FRANCE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) □ 232

TABLE 241 □ FRANCE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) □ 233

TABLE 242 □ FRANCE: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) □ 233

TABLE 243 □ FRANCE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) □ 233

TABLE 244 □ FRANCE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) □ 234

TABLE 245 □ FRANCE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) □ 234

TABLE 246 □ FRANCE: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) □ 234

Custom Antibody Market by Service (Development, Purification, Fragmentation, Labeling), Type (mAbs, pAbs, rAbs), Source (Rabbit, Mice), Application (Research, Therapeutics), Indication (Oncology, Immunology, Infectious, CVD) - Global Forecast to 2029

Market Report | 2024-06-05 | 377 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Zip Code*

Country*

Date

2026-03-05

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com